Abstract

SEMAGLUTIDE – NOVEL DRUG FOR TREATMENT OF T2DM ITS SAFETY AND EFFICACY

K. Nabeen Patra*, Prashant Kumar Sahu and Mihir Prasad Choudhry

ABSTRACT

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes mellitus. It works by increasing the production of insulin and reducing the production of glucagon, which in turn helps to lower blood sugar levels. Clinical trials have shown that semaglutide is highly effective in reducing HbA1c levels, which is a measure of average blood sugar levels over the previous three months. In addition, it has been shown to reduce body weight, blood pressure, and cardiovascular risk factors in people with type 2 diabetes. The SUSTAIN clinical trial program evaluated the safety and efficacy of semaglutide compared to other GLP-1 receptor agonists in a large population of people with type 2 diabetes mellitus. Results showed that semaglutide was superior to other GLP-1 receptor agonists in reducing HbA1c levels and body weight. Another clinical trial, the PIONEER program, evaluated the safety and efficacy of semaglutide in people with type 2 diabetes who were also at high risk for cardiovascular disease. Results showed that semaglutide reduced the risk of cardiovascular events compared to a placebo. Overall, semaglutide is a highly effective treatment for type 2 diabetes, with a favorable safety profile and the potential to reduce the risk of cardiovascular events in people at high risk.

Keywords: Semaglutide, GLP-1, type 2 diabetes mellitus, insulin, glucagon, lower blood sugar levels, clinical trials, HbA1c, body weight, blood pressure, cardiovascular risk factors, sustain, safety, efficacy, agonists, superior, PIONEER program, placebo, safety pr